Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience.

Journal of Crohn's & colitis - 1 Mar 2012

Sprakes Michael B, Ford Alexander C, Warren Lisa, Greer Dan, Hamlin John

Abstract excerpt

BACKGROUND: Infliximab is licenced for use in Crohn's disease (CD). Trial data demonstrate that infliximab is effective for inducing remission of active CD, healing fistulising CD, and preventing relapse once in remission. However, long-term data regarding efficacy, safety, and predictors of response are still emerging. AIM: To examine these issues in a large cohort of patients who received infliximab for CD....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Inflammatory Agents
Share to Azathioprine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Crohn Disease

Share to Immunosuppressive Agents

Share to Infliximab

Share to Kaplan-Meier Estimate

Share to Methotrexate

Share to Remission Induction

Source

Identifiers

PMID: 22325168
DOI: 10.1016/j.crohns.2011.07.011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience.PMID 22325168Read ↗

Clinical experience with adalimumab in a multicenter Swiss cohort of patients with Crohn's disease.Semantic proximity Read ↗

Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.Semantic proximity Read ↗

Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn’s disease patients over three yearsSemantic proximity Read ↗

Extended Analysis Identifies Drug-Specific Association of 2 Distinct HLA Class II Haplotypes for Development of Immunogenicity to Adalimumab and InfliximabSemantic proximity Read ↗

Incidence, prevalence and clinical outcome of anaemia in inflammatory bowel disease: a population-based cohort study.Semantic proximity Read ↗

To evaluate the predictive effect of vitamin D on clinical outcomes of infliximab treated Crohn’s disease patients in western ChinaSemantic proximity Read ↗

Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn’s Disease Patients: From Bedside to Bioinformatics.Semantic proximity Read ↗

Infliximab serum concentrations and disease activity in perianal fistulizing Crohn's disease: a cross-sectional studySemantic proximity Read ↗

Candidate Serum Markers in Early Crohn's Disease: Predictors of Disease Course.Semantic proximity Read ↗

Recent advances: Personalised use of current Crohn's disease therapeutic options.Semantic proximity Read ↗

Personalizing therapy for inflammatory bowel diseases.Semantic proximity Read ↗

Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.